BACKGROUND: Although improvement in left ventricular (LV) function has been shown to portend superior short-term outcomes in patients with heart failure undergoing cardiac resynchronization therapy (CRT), the durability of this effect at 5 years has not been established. OBJECTIVE: To determine the long-term outcomes of patients undergoing CRT on the basis of the degree of echocardiographic response. METHODS: We extracted clinical data on a cohort of 880 consecutive patients undergoing the new implantation of a CRT device between September 30, 2003, and August 6, 2007. Patients with an ejection fraction (EF) ≤35% undergoing initial CRT implantation, with an available pre-CRT and follow-up echocardiogram, were included in the final cohort. On the basis of changes in LVEF, patients were categorized into "nonresponders" (change in EF ≤4%), "responders" (EF change 5%-20%), and "super-responders" (change in EF >20%). A Cox multivariate model was performed to determine the effect of response on long-term survival free of LV assist device or heart transplant. RESULTS: A total of 526 patients met inclusion criteria, of whom 196 (37.3%) were classified as nonresponders, 236 (44.9%) as "responders," and 94 (17.9%) as "super-responders." In multivariate analysis, "super-responders" had the best survival and nonresponders the worst over a mean of follow-up of 5.3 ± 2.4 years. At 5 years, survival free of LV assist device or heart transplant among super-responders was 82%; responders, 70%; and nonresponders, 48%. CONCLUSIONS: In patients with heart failure undergoing CRT, survival benefit is durable at 5 years of follow-up and its degree intimately tied to the level of improvement in ventricular function. The prognosis of nonresponders is exceptionally poor.
BACKGROUND: Although improvement in left ventricular (LV) function has been shown to portend superior short-term outcomes in patients with heart failure undergoing cardiac resynchronization therapy (CRT), the durability of this effect at 5 years has not been established. OBJECTIVE: To determine the long-term outcomes of patients undergoing CRT on the basis of the degree of echocardiographic response. METHODS: We extracted clinical data on a cohort of 880 consecutive patients undergoing the new implantation of a CRT device between September 30, 2003, and August 6, 2007. Patients with an ejection fraction (EF) ≤35% undergoing initial CRT implantation, with an available pre-CRT and follow-up echocardiogram, were included in the final cohort. On the basis of changes in LVEF, patients were categorized into "nonresponders" (change in EF ≤4%), "responders" (EF change 5%-20%), and "super-responders" (change in EF >20%). A Cox multivariate model was performed to determine the effect of response on long-term survival free of LV assist device or heart transplant. RESULTS: A total of 526 patients met inclusion criteria, of whom 196 (37.3%) were classified as nonresponders, 236 (44.9%) as "responders," and 94 (17.9%) as "super-responders." In multivariate analysis, "super-responders" had the best survival and nonresponders the worst over a mean of follow-up of 5.3 ± 2.4 years. At 5 years, survival free of LV assist device or heart transplant among super-responders was 82%; responders, 70%; and nonresponders, 48%. CONCLUSIONS: In patients with heart failure undergoing CRT, survival benefit is durable at 5 years of follow-up and its degree intimately tied to the level of improvement in ventricular function. The prognosis of nonresponders is exceptionally poor.
Authors: Abdul Ghani; Peter Paul H M Delnoy; Ahmet Adiyaman; Jan Paul Ottervanger; Anand R Ramdat Misier; Jaap Jan J Smit; Arif Elvan Journal: Clin Cardiol Date: 2017-03-14 Impact factor: 2.882
Authors: John Rickard; Divyang Patel; Carolyn Park; Joseph E Marine; Sunil Sinha; W H Wilson Tang; Niraj Varma; Bruce L Wilkoff; David Spragg Journal: JACC Clin Electrophysiol Date: 2020-10-28
Authors: Jetske van 't Sant; Aernoud T L Fiolet; Iris A H ter Horst; Maarten J Cramer; Mirjam H Mastenbroek; Wouter M van Everdingen; Thomas P Mast; Pieter A Doevendans; Henneke Versteeg; Mathias Meine Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240
Authors: Niraj Varma; David O'Donnell; Mohammed Bassiouny; Philippe Ritter; Carlo Pappone; Jan Mangual; Daniel Cantillon; Nima Badie; Bernard Thibault; Brian Wisnoskey Journal: J Am Heart Assoc Date: 2018-02-06 Impact factor: 5.501
Authors: Serge C Harb; Saleem Toro; Jennifer A Bullen; Nancy A Obuchowski; Bo Xu; Kevin M Trulock; Niraj Varma; John Rickard; Richard Grimm; Brian Griffin; Scott D Flamm; Deborah H Kwon Journal: Open Heart Date: 2019-07-05
Authors: Niraj Varma; Robert C Bourge; Lynne Warner Stevenson; Maria Rosa Costanzo; David Shavelle; Philip B Adamson; Greg Ginn; John Henderson; William T Abraham Journal: J Am Heart Assoc Date: 2021-02-25 Impact factor: 5.501
Authors: J van 't Sant; T P Mast; M M Bos; I A Ter Horst; W M van Everdingen; M Meine; M J Cramer Journal: Neth Heart J Date: 2016-01 Impact factor: 2.380